Thyroid-stimulating hormone (TSH) levels obtained one month after the cessation of anti-thyroid drug treatment were assessed retrospectively for possible use in predicting outcome in 50 patients with a clinical diagnosis of Graves' disease. Thirty-four patients remained in remission at the end ofthe follow-up period and 16 patients relapsed. Although a TSH level of < 1.2 mU/l did not discriminate between the two groups, none of the 24 patients who had TSH levels of >1.2 mU/l relapsed during the follow-up period, making early discharge from the thyroid clinic possible for these patients.
Introduction
An ability to predict the outcome of antithyroid drug therapy in patients with thyrotoxicosis would be of great value. The introduction in the mid 1980s ofimmunoradiometric assays for thyroid-stimulating hormone (TSH) raised the possibility of utilising this assay for assessing outcome. However, Wilson et all found that, in patients suffering from Graves' disease treated with carbimazole and triiodothyronine (T3), TSH immunoradiometric assays had no predictive value but thyroid receptor antibody levels predicted 90% of relapses and remissions. Workers from the same group have more recently confirmed the high specificity and sensitivity of thyroid receptor antibody levels in their hands.2 As thyroid receptor antibody assays are not routinely available in the majority of district general hospitals, it seemed appropriate to investigate the use ofTSH immunoradiometric assays further, as these are now routinely used.
Patients and methods
Fifty patients, for whom a TSH level one month after stopping treatment was available, and who had been further followed for at least one year, were assessed retrospectively to investigate whether TSH immunoradiometric levels could be of use in assessing the probability of relapse or remission. In all cases treatment was tailed off gradually whether titration alone or a block and supplement regime using antithyroid drugs and thyroxine had been used.
The patients (45 females, five males) were followed for at least one year following cessation of drug therapy. Patients with hyperthyroidism secondary to multi-nodular goitre were excluded, although minor nodular change was present clinically in some of the older patients assessed as having Graves' disease by the presence of ocular signs. Patients included, therefore, either had predominantly smooth enlargement ofthe thyroid, with or without eye signs, or some nodularity of the gland with definite ocular signs of Graves' disease. Routine technetium-99m images were not performed but all patients had biochemical and clinical evidence of hyperthyroidism prior to treatment.
The treatment regime consisted initially of carbimazole 30-45 mg daily or an equivalent dose of propylthiouracil. The dose was titrated according to the clinical status of the patient and the results of thyroid function tests. Prior to stopping treatment patients were taking either 5 mg of carbimazole or 50 mg of propylthiouracil. Nine patients, who either became rapidly hypothyroid or had other difficulties with the titration regime, had an appropriate dose of thyroxine added to their regime, together with a blocking dose of antithyroid drugs. At the end of the treatment period, thyroxine was stopped and the antithyroid drug tailed off over a period of a month. All patients were treated for at least one year except one who was treated for six months.
Samples were obtained for TSH immunoradiometric measurements at one month following cessation oftreatment. The sample was also assayed for total thyroxine and, if the TSH measurement were suppressed, for free triiodothyronine. The patients included in this survey all had thyroxine and, when appropriate, free triiodothyronine levels within the laboratory reference range. All patients had been followed at approximately three-monthly intervals for a minimum of one year. Recurrence was first detected biochemically but of this group all but one, who had rapidly changing thyroid function, were also clinically toxic.
TSH immunoradiometric levels were measured using one of two assays. For most of the survey the Sucrosep (Boots Celltech) assay was group.bmj.com on July 6, 2017 -Published by http://pmj.bmj.com/ Downloaded from used. When this became unavailable the Delphia (Pharmacia) assay was introduced. The correlation of the two assays over a range of Sucrosep TSH values of 0.13-4.7 mU/l was r = 0.93 (p = <0.01). The between-assay coefficients of variation of the two assays were: Sucrosep: 6.3% at a value of 28 mU/l, 6.5% at 6.0 mU/l and 8.5% at 1.2 mU/l. Delphia: 5.3% at a value of 22 mU/l and 6.1% at a value of 1.1 mU/l. The data were analysed using the Wilcoxon Rank test.
Results
The figure shows the TSH values one month after stopping treatment in two groups of patients, those who had become thyrotoxic by the end of the year of follow-up and those who remained in remission. Thirty four patients (30 female, four male: mean age ± sd, 43 ± 14 years) were in remission at one year; 16 patients (15 female, one male: mean age 37 ± 13 years) relapsed during the year of follow-up. The mean TSH level for the remission group was 1.37 ± 0.82 mU/l and for the recurrence group was 0.43 ± 0.38 mU/i. The TSH levels between the recurrence and remission groups were statistically significantly different (p<0.01). 
